Prader-Willi Syndrome (PWS) Market will grow at highest pace owing to increasing diagnosis rates

Prader-Willi Syndrome (PWS) Market will grow at highest pace owing to increasing diagnosis rates

Prader-Willi syndrome (PWS) is a rare genetic disorder that causes a variety of physical symptoms including low muscle tone, short stature, incomplete sexual development, and a chronic feeling of hunger. The lack of the Prader-Willi imprinting center on chromosome 15 results in hyperphagia, developmental delay, hypogonadism, and typically mild to moderate intellectual disability. PWS is a complex genetic condition that can affect anyone regardless of gender or ethnicity. With no known cure, treatment aims to manage symptoms and improve quality of life.

The Prader-Willi Syndrome (PWS) market is estimated to be valued at USD 0.916 Bn in 2024 and is expected to reach USD 1.47 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7% from 2024 to 2031.

Key Takeaways
Key players operating in the Prader-Willi syndrome treatment Market include Pfizer, Novartis, Eli Lilly, and Company, Novo Nordisk, and Allergan. These players are focused on developing new products to treat hyperphagia, cognitive impairment, and hypogonadism associated with PWS.

The growing diagnosis rates of Prader-Willi Syndrome (PWS) Market is a major factor driving the demand for treatment procedures and medications. According to the Prader-Willi Syndrome Association USA, the occurrence rate of PWS is estimated to be 1 in 10,000 to 30,000 live births. The increasing awareness about the symptoms and management of the disorder is also contributing to its early detection.

Technological advancements have enabled the development of medications such as oxytocin nasal spray and growth hormone therapy that effectively manage the symptoms of hyperphagia and growth impairment associated with PWS. New drug candidates targeting hyperphagia, abdominal fat deposition, and hypersomnia associated with the disorder are currently under clinical trials.

Market Trends
The increasing preference for gene therapy over conventional drug therapies due to its higher efficacy and safety is a key trend in the PWS treatment market. Researchers are investigating gene replacement and genome editing therapies as potential cures for PWS.

Non-invasive brain stimulation techniques such as repetitive transcranial magnetic stimulation are being actively researched for managing cognitive dysfunction associated with PWS. Some studies have demonstrated their potential in reducing compulsive behaviors and improving attention in PWS patients.

Market Opportunities
There is potential to develop drugs for treating hypersomnia, one of the less addressed symptoms of PWS. Currently available treatment options such as stimulant medications are not very effective for this symptom.

Behavioral therapies in combination with drug treatments provide a multi-disciplinary management approach for hyperphagia, which still remains difficult to control. Integrating virtual reality and digital therapeutics can help optimize behavioral therapy for PWS patients.

Impact of COVID-19 on Prader-Willi Syndrome (PWS) Market Growth
The COVID-19 pandemic has adversely impacted the global Prader-Willi syndrome (PWS) market. The strict lockdowns imposed worldwide delayed clinical trials and drug development processes. It also disrupted the supply chain of key raw materials used in manufacturing PWS drugs. All these factors negatively influence the market growth in the short term.

However, the prioritization of rare disease treatment is expected to drive the market's post-COVID growth. Many countries are allocating increased funding for rare disease research to minimize the impact of pandemic on patients. The rising focus on immunodeficiency disorder management amid the pandemic may also boost the demand for PWS drugs.

Telemedicine and remote monitoring are helping doctors continue the supervision of PWS patients during lockdowns. The increased healthcare spending by governments to combat COVID-19 can accelerate the market's recovery. Initiatives to ensure an uninterrupted drug supply and speed up clinical trials will support long-term growth.

Geographical Concentration of PWS Market
The United States accounts for the major share of the global PWS market in terms of value. This is due to the presence of advanced healthcare facilities, high healthcare expenditure, and growing public awareness about rare conditions. The country is also a front-runner in conducting clinical trials and approving new treatment therapies. Several key pharmaceutical manufacturers are based in the US, expanding domestic market size.

Fastest Growing Region in PWS Market
Asia Pacific region is projected to experience the highest growth in the PWS market during the forecast period. This is attributed to factors like increasing healthcare expenditure, growing adoption of modern treatment methods, and rising per capita income in countries like China and India. Greater patient volumes also allow stakeholders to increase research collaborations and investments in the region. Additionally, improving regulatory frameworks are fueling the regional market

Get More Insights On- Prader-Willi Syndrome (PWS) Market

Get This Report in Japanese Language: プラダー・ウィリー症候群市場

Get This Report in Korean Language: 프라더-윌리 증후군 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)